Post-earnings recap
Reported
Tue, Jun 23, 2026
EPS actual
$2.50
EPS est.
$2.18
EPS surprise
+14.84%
1-day move
+1.38%
ICON Public Limited Company reported better-than-expected earnings per share, which contributed to a positive stock reaction, with shares rising by 1.38%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance. Investors may view the EPS beat as a sign of operational strength, but the lack of revenue data and guidance could lead to cautious sentiment moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.50 | $2.43 | +14.84% |
| Revenue | N/A | $2.0B | N/A |
No transcript is on record, and the analysis is based on numerical results only.
ICON Public Limited Company operates in the health care sector, specifically within life sciences tools and services. The company plays a crucial role in supporting pharmaceutical and biotechnology companies with clinical development and commercialization services, which are essential for bringing new drugs to market.
Last quarter
In the last quarter, ICON reported an EPS of $2.52, slightly above expectations, which led to a positive stock reaction of +4.04% the following day. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.
Management promises and guidance
EPS beat streak
2Q
EPS beat rate
75%
Avg EPS surprise
+5.31%
Avg 1-day reaction
+1.22%
Analysts expect ICON to report strong earnings driven by consistent demand in the life sciences sector. The consensus EPS of $2.43 reflects optimism about the company's ability to maintain profitability.
Bull case
If ICON beats EPS expectations and shows strong revenue growth, it could signal robust demand for their services, potentially leading to a significant stock price increase.
Bear case
Conversely, if the company misses earnings expectations or reveals challenges in revenue growth, it could raise concerns about its market position and lead to a decline in stock price.
Key metrics to watch
EPS
$2.43Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating profits.
Revenue
$2.0BRevenue figures will indicate the overall demand for ICON's services and how well they are performing in the competitive life sciences market.
The print will turn on these.
Q1
Will EPS exceed the consensus estimate of $2.43?
A beat on EPS would reinforce investor confidence in ICON's profitability and could lead to a positive stock reaction.
Q2
What is the revenue forecast for this quarter?
Revenue figures will provide insight into demand for ICON's services and overall market performance, which is critical for future growth.
—
Est. EPS
$1.38
Est. Rev
$745M
Impl. Move
±9.8%
Why consensus could be wrong
The Street may be underestimating ICON's ability to leverage recent technological advancements to drive revenue growth, which could lead to better-than-expected earnings.
Supporting evidence
The company has consistently beaten EPS estimates in the past, suggesting strong operational management.
Options pricing indicates a higher expected move than historical averages, reflecting potential for significant surprises.
Recent trends in the life sciences sector indicate increasing demand for clinical development services.
Key risk
If revenue growth exceeds $2.1B, it could challenge the current consensus and shift market sentiment positively.
Pre-commit to what would confirm each case.
The market is closely watching ICON's ability to maintain profitability while navigating a competitive landscape in the life sciences sector.
Bull confirmed if
An EPS of $2.50 or higher would confirm strong operational performance and investor confidence.
Bear confirmed if
An EPS below $2.30 would raise concerns about profitability and could lead to a negative market reaction.
What the market is pricing for the move.
Implied Move
±2.09%
Historical Avg
±1.8%
The options market is pricing in a modest move around the earnings report, suggesting that traders expect some volatility but not a dramatic shift in stock price.
Options are pricing ±2.1% while ICLR has averaged ±1.8% over the last 8 prints — setup is roughly in line with history.
ATM IV
0.6%
30d HV
74.0%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
108.21%
of float
Insider
0.44%
of float
Holders
619
institutions
Top Holders· as of Jun 2026
Artisan Partners Limited Partnership
8,636,406 sh · $1.4B
11.31%
4.3%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If ICON beats expectations, history suggests a potential stock increase of around +1.22%, confirming strong demand and operational efficiency.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance from management.
Miss
A miss on earnings could lead to a decline of about -0.96%, signaling potential issues in demand or operational challenges.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
House only
Est. Notional
$15,001.00–$50,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Wellington Management Group, LLP
5,320,054 sh · $872.9M
6.97%
-10.0%
FMR, LLC
5,271,321 sh · $864.9M
6.90%
26.3%
Invesco Ltd.
5,264,236 sh · $863.8M
6.89%
35.7%
Harris Associates L.P.
4,468,146 sh · $733.1M
5.85%
2.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded Aug 14, 2026 · disclosed Sep 1, 2026
$15,001.00–$50,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.